1. Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
- Author
-
Hengeveld, P. J., Schilperoord-Vermeulen, J., van der Klift, M. Y., Dubois, J. M. N., Kolijn, P. M., Kavelaars, F. G., Rijken, M., Dobber, J. A., Nasserinejad, K., Kersting, S., Westerweel, P. E., Kater, A. P., Langerak, A. W., and Levin, M-D.
- Subjects
CHRONIC lymphocytic leukemia ,VENETOCLAX ,IMMUNE reconstitution inflammatory syndrome ,CHRONIC leukemia - Abstract
Moreover, in treatment-naïve patients receiving zanubrutinib, obinutuzumab and venetoclax, achieving a 2.6 log-reduction (400-fold) in MRD between baseline and cycle 5 was predictive of reaching undetectable MRD at cycle 8 and retaining MRD < 10 SP -5 sp after 1 year of treatment cessation [[9]]. In conclusion, in treatment-naïve CLL patients treated with venetoclax and obinutuzumab, high levels of early MRD (>10 SP -2 sp ) and a slow rate of MRD eradication, measured after 11 weeks of treatment, predicted failure to reach uMRD (<10 SP -5 sp ) at the end of induction treatment. Dear Editor, Measurable residual disease (MRD) is an important post-treatment biomarker that predicts progression-free survival (PFS) following fixed-duration treatment in chronic lymphocytic leukemia (CLL) [[1]]. Patients reaching MRD < 10 SP -5 sp at EOiT had higher MRD, compared to patients that failed to reach MRD < 10 SP -5 sp (mean MRD 5.1 versus 2.9, I P i = 0.02). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF